Moreover, a single marker may not be sufficient to predict ICI response, as shown in the Checkmate 026 study for NSCLC, where patients with a combination of high TMB and strong PD-L1 positivity showed longer progression-free survival (PFS) than patients with positivity of either marker (Peters et al. 2017). Here, CD274 is linked to non-small cell lung carcinoma.